EP0958364A4 - IMMUNOTHERAPY AND IMPROVED VACCINES - Google Patents

IMMUNOTHERAPY AND IMPROVED VACCINES

Info

Publication number
EP0958364A4
EP0958364A4 EP97912961A EP97912961A EP0958364A4 EP 0958364 A4 EP0958364 A4 EP 0958364A4 EP 97912961 A EP97912961 A EP 97912961A EP 97912961 A EP97912961 A EP 97912961A EP 0958364 A4 EP0958364 A4 EP 0958364A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapy
improved vaccines
vaccines
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97912961A
Other languages
German (de)
French (fr)
Other versions
EP0958364A1 (en
Inventor
Jong J Kim
Velpandi Ayyavoo
Bin Wang
Jean D Boyer
David B Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Publication of EP0958364A1 publication Critical patent/EP0958364A1/en
Publication of EP0958364A4 publication Critical patent/EP0958364A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
EP97912961A 1996-10-23 1997-10-23 IMMUNOTHERAPY AND IMPROVED VACCINES Withdrawn EP0958364A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2861396P 1996-10-23 1996-10-23
US2861P 1996-10-23
PCT/US1997/019502 WO1998017799A1 (en) 1996-10-23 1997-10-23 Immunotherapy and improved vaccines

Publications (2)

Publication Number Publication Date
EP0958364A1 EP0958364A1 (en) 1999-11-24
EP0958364A4 true EP0958364A4 (en) 2001-10-31

Family

ID=21844431

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97912961A Withdrawn EP0958364A4 (en) 1996-10-23 1997-10-23 IMMUNOTHERAPY AND IMPROVED VACCINES

Country Status (8)

Country Link
EP (1) EP0958364A4 (en)
JP (3) JP2001507216A (en)
KR (4) KR100780158B1 (en)
CN (2) CN1257976C (en)
AU (1) AU729579B2 (en)
BR (1) BR9712852A (en)
CA (3) CA2745736C (en)
WO (1) WO1998017799A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752658B2 (en) * 1998-05-06 2002-09-26 Association Francaise Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
AU2002301344B2 (en) * 1998-05-06 2005-01-13 Association Francais Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
AU3827699A (en) * 1998-05-07 1999-11-23 Akzo Nobel N.V. Use of interleukin-18 as vaccine adjuvant
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
KR20010103788A (en) * 1999-03-03 2001-11-23 멕코나시 에블린 에이치. Vaccines and Gene Therapy Compositions and Methods of Making and Using the Same
EE200100552A (en) 1999-04-23 2002-12-16 Pharmexa A/S A method of suppressing growth factor IL-5 activity in vivo, an IL-5 analogue, a nucleic acid fragment encoding it and use in the preparation of an immunogenic composition
ID30407A (en) 1999-05-13 2001-11-29 American Cyanamid Co COMBINATION FORM FOR ADDITION MATERIALS
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
EP1246848A1 (en) * 1999-12-27 2002-10-09 University Of Manitoba GENETIC VACCINES FOR THE PRODUCTION OF CHICKEN EGG-YOLK ANTIBODIES AGAINST ENTEROTOXIGENIC i ESCHERICHIA COLI /i AND OTHER PATHOGENS
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7754201B2 (en) 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
US7092633B2 (en) 2000-11-14 2006-08-15 University Of Texas System Board Of Regents System and method for configuring optical circuits
JP2002221520A (en) * 2001-01-29 2002-08-09 Sumitomo Chem Co Ltd Predicting immune type
MY146518A (en) * 2001-03-27 2012-08-15 Univ Saskatchewan Methods to culture circovirus.
KR20030012199A (en) * 2001-07-31 2003-02-12 (주)지노첵 Dna vaccine comprising cytokine gene as active ingredient
ATE444310T1 (en) * 2002-01-17 2009-10-15 Polymun Scient Immunbio Forsch ANTIDIOTYPIC ANTIBODIES THAT INDUCE HIV-1 NEUTRALIZING ANTIBODIES
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
KR101114784B1 (en) 2002-11-12 2012-02-27 예일 유니버시티 Adenoviral Vector Vaccine
US8663622B2 (en) 2002-12-16 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant vaccine viruses expressing IL-15 and methods using the same
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
WO2004069272A2 (en) * 2003-02-05 2004-08-19 Movecare Ltd Adjuvant combination for use in the immunization of a mamal comprising il2 and il12
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
EP1687334B1 (en) 2003-11-24 2014-01-08 MicroVAX, LLC Mucin antigen vaccine
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
SG149013A1 (en) 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
SI2336147T1 (en) 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy A beta immunogenic peptide carrier conjugates and methods of producing same
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CN101228272A (en) * 2005-04-20 2008-07-23 生物载体株式会社 Intranasally administered gene vaccine with high safety for the treatment of Alzheimer's disease
DK2041270T3 (en) 2006-07-13 2014-01-27 Wyeth Llc Preparation of glycoproteins
MX2009004519A (en) 2006-11-03 2009-05-12 Wyeth Corp Glycolysis-inhibiting substances in cell culture.
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2265715B1 (en) 2008-04-04 2016-12-28 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
WO2010126766A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CN102370979B (en) * 2011-10-10 2013-05-01 中国人民解放军第四军医大学 Building method for autovaccine by aiming at human TNF(Tumor Necrosis Factor)-alpha molecule
CA2879443A1 (en) 2012-07-19 2014-01-23 Zoetis Llc Bovine influenza virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
CA2907098A1 (en) 2013-03-15 2014-09-25 Zoetis Services Llc Cross-protection of bovines against b. trehalosi infection by a multi-valent vaccine
MX428954B (en) * 2013-03-15 2025-11-13 Univ Pennsylvania IMPROVED VACCINATION AGAINST HUMAN GROWTH HORMONE-RELEASING HORMONE (GHRH).
WO2014140894A2 (en) * 2013-03-15 2014-09-18 Bioven 3 Limited Self-assembling synthetic proteins
DK3334454T3 (en) 2015-08-14 2022-11-14 Zoetis Services Llc Mycoplasma-Bovis Assemblages
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
KR20190141695A (en) 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 Combination Cancer Immunotherapy
CN111479590A (en) 2017-12-13 2020-07-31 艾诺奥医药品有限公司 Cancer vaccines targeting mesothelin and their use
CA3084135C (en) 2017-12-13 2024-03-05 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting muc16 and uses thereof
RU2759681C1 (en) 2017-12-13 2021-11-16 Иновио Фармасьютикалз, Инк. Anticancer vaccines targeting boris and methods of their application
CN111479583A (en) 2017-12-13 2020-07-31 艾诺奥医药品有限公司 Cancer vaccines targeting survivin and their uses
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
CN110170049B (en) * 2019-06-01 2023-07-04 山西农业大学 Cytokine gene adjuvant for chicken coccidiosis live vaccine
EP4493212A1 (en) 2022-03-14 2025-01-22 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001575A1 (en) * 1982-10-11 1984-04-26 Nat Biolog Standards Board Polypeptides useful in vaccination against enteroviruses
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612983B2 (en) * 1986-08-01 1991-07-25 Australian National University, The Recombinant vaccine
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5238823A (en) * 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001575A1 (en) * 1982-10-11 1984-04-26 Nat Biolog Standards Board Polypeptides useful in vaccination against enteroviruses
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRONTE V ET AL: "IL-2 ENHANCES THE FUNCTION OF RECOMBINANT POXVIRUS-BASED VACCINES IN THE TREATMENT OF ESTABLISHED PULMONARY METASTASES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, no. 10, 15 May 1995 (1995-05-15), pages 5282 - 5292, XP002030630, ISSN: 0022-1767 *
CHOW YEN-HUNG ET AL: "Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.", JOURNAL OF VIROLOGY, vol. 71, no. 1, 1997, pages 169 - 178, XP002176596, ISSN: 0022-538X *
GREENBERGER MJ ET AL.,: "Il-12 gene therapy protects mice in lethal Klebsiella pneumonia", J IMMUNOL., vol. 157, no. 7, 1 October 1997 (1997-10-01), XP001015488 *
IRVINE K R ET AL: "CYTOKINE ENHANCEMENT OF DNA IMMUNIZATION LEADS TO EFFECTIVE TREATMENT OF ESTABLISHED PULMONARY METASTASES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 156, 1996, pages 238 - 245, XP002030631, ISSN: 0022-1767 *
LIEU FRANCIS H L ET AL: "Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: Implications for immune gene therapy.", CANCER GENE THERAPY, vol. 4, no. 3, 1997, pages 167 - 175, XP001019756, ISSN: 0929-1903 *
RAKHMILEVICH A L ET AL: "GENE GUN-MEDIATED SKIN TRANSFECTION WITH INTERLEUKIN 12 GENE RESULTS IN REGRESSION OF ESTABLISHED PRIMARY AND METASTATIC MURINE TUMORS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 93, 1 June 1996 (1996-06-01), pages 6291 - 6296, XP001074604, ISSN: 0027-8424, DOI: DOI:10.1073/PNAS.93.13.6291 *
See also references of WO9817799A1 *
XIANG Z ET AL: "MANIPULATION OF THE IMMUNE RESP0NSE TO A PLASMID-ENCODED VIRAL ANTIGEN BY COINOCULATION WITH PLASMIDS EXPRESSING CYTOKINES", IMMUNITY, CELL PRESS, US, vol. 2, no. 2, 1 February 1995 (1995-02-01), pages 129 - 135, XP000670098, ISSN: 1074-7613 *

Also Published As

Publication number Publication date
AU5002297A (en) 1998-05-15
AU729579B2 (en) 2001-02-01
CN1868545A (en) 2006-11-29
JP2009232860A (en) 2009-10-15
CN1257976C (en) 2006-05-31
CA2269074A1 (en) 1998-04-30
JP2001507216A (en) 2001-06-05
CA2745736A1 (en) 1998-04-30
KR100629835B1 (en) 2006-09-29
JP2008194046A (en) 2008-08-28
KR20070108418A (en) 2007-11-09
CN1242045A (en) 2000-01-19
CA2745736C (en) 2016-11-22
KR20050053796A (en) 2005-06-08
EP0958364A1 (en) 1999-11-24
KR100780158B1 (en) 2007-11-27
CA2751712A1 (en) 1998-04-30
KR20000052710A (en) 2000-08-25
KR20050008860A (en) 2005-01-21
BR9712852A (en) 1999-11-16
CA2751712C (en) 2016-11-22
WO1998017799A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
BR9711853A (en) Vaccines
DE69704612D1 (en) DENTAL DIMENSIONS AND DENTAL PRODUCT
ATE253338T1 (en) FASTENING DEVICE AND PROSTHESIS PROVIDED THEREOF
DE69935606D1 (en) ADJUVANCY SYSTEMS AND VACCINES
ID16292A (en) 2-ARIL SUBSTITUTIONAL PIRIDINS
DE69717440D1 (en) AGGREGATTRÄGER AND ATTACHED OLEFINPOLYMERIZATION CATALYSTS
DE59711118D1 (en) Spikeln, increase and decrease
DE69732084D1 (en) PULLEYING METHOD AND CHARGER
DE19681408D2 (en) Addition-curing 2-component silicone materials
DK0863332T3 (en) Curved disc device
EP0958373A4 (en) Vaccines
DE59705120D1 (en) Chopper and conveyor
DE69725663D1 (en) Billing procedure and system
HUP9701586A3 (en) Improved inactivated vaccines
DE69709876D1 (en) ORTHODONTIC AND PERIODONTOLOGICAL DEVICES
ZA9711565B (en) Vaccine
ID22281A (en) SUBSTITUTIONAL PROPIONIL DEGREES
DE69833641D1 (en) LOAD-LOADING AND CONTROLLABLE UNIT
DE59711777D1 (en) HYDROPUMP AND HYDROMOTOR
DE59812220D1 (en) HOLDING AND WEARBAND
GB9609252D0 (en) Vaccines
SE9602287D0 (en) Novel protein and methods for its use
FI960008A0 (en) Foerfarande and anordning med vilken en jonproduktionselektrod haolls ren
KR970051241U (en) Umbrella and umbrella
FI962741A0 (en) Sollins and braennpunktsvaermare i kombination med vaermeacumulator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/18 A, 7A 61K 48/00 B, 7A 61K 31/00 B, 7C 12N 15/86 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010918

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020923

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/54 20060101ALI20110211BHEP

Ipc: A61K 48/00 20060101ALI20110211BHEP

Ipc: C12N 15/19 20060101AFI20110211BHEP

RTI1 Title (correction)

Free format text: ENHANCEMENT OF DNA IMMUNIZATION BY CO-EXPRESSION OF IL-12 SUBUNITS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110727